{"id":"NCT03472040","sponsor":"BioCryst Pharmaceuticals","briefTitle":"A Long Term Safety Study of BCX7353 in Hereditary Angioedema","officialTitle":"An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Angioedema","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2018-02-16","primaryCompletion":"2022-04-27","completion":"2022-04-27","firstPosted":"2018-03-21","resultsPosted":"2023-06-18","lastUpdate":"2023-06-18"},"enrollment":387,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Hereditary Angioedema","HAE","Prophylaxis"],"interventions":[{"type":"DRUG","name":"BCX7353","otherNames":[]}],"arms":[{"label":"BCX7353 150 mg once daily","type":"EXPERIMENTAL"}],"summary":"This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II Hereditary Angioedema (HAE).","primaryOutcome":{"measure":"Safety & Tolerability","timeFrame":"Up to 96 weeks (US) / 216 weeks (Rest of World (ROW)).","effectByArm":[{"arm":"110 mg Followed by 150 mg Berotralstat","deltaMin":94,"sd":null},{"arm":"150 mg Berotralstat","deltaMin":240,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":87,"countries":["United States","Australia","Austria","Denmark","France","Germany","Hong Kong","Hungary","Israel","Italy","New Zealand","North Macedonia","Poland","Serbia","Slovakia","South Africa","South Korea","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["40490218","38020288","38006972","36408587","35820771","34161665"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":100},"commonTop":["Nasopharyngitis","Headache","Diarrhoea","Upper respiratory tract infection","Abdominal pain"]}}